These beneficial effects, in addition to metabolic improvements in glycemic control and weight reduction, provide a compelling rationale for the further study of GLP-1 RAs in non-diabetic kidney diseases like AS
Last week, the US Food and Drug Administration announced that tirzepatide is no longer in shortage
PubMed Coskun, T., Urva, S., Roell, W.C., Qu, H., Loghin, C., Moyers, J.S., OFarrell, L.S., Briere, D.A., Sloop, K.W., Thomas, M.K., Pirro, V., Wainscott, D.B., Willard, F.S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R.E., Haupt, A., & Milicevic, Z
Breaking News Merck Enters Exclusive Alliance with Hansoh Pharma for Oral GLP-1 Candidate Hansoh Pharma will receive $112 million upfront and is eligible to receive up to $1.9 billion in milestone payments